Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$20.08 USD
-0.58 (-2.81%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $20.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SNDX 20.08 -0.58(-2.81%)
Will SNDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SNDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNDX
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
SNDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
Other News for SNDX
Syndax initiated with bullish view at Jefferies, here's why
Syndax price target raised by $2 at Stifel, here's why
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
Syndax: Gearing Up For Launches
TD Cowen Sticks to Its Buy Rating for Syndax Pharmaceuticals (SNDX)